Beam Therapeutics (MEX:BEAM) Current Accrued Expense: MXN301 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:BEAM Beam Therapeutics Inc MEX:BEAM
68 GF Score
Price MXN454.00
GF Value MXN445.80
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Beam Therapeutics Current Accrued Expense?

Beam Therapeutics MEX:BEAM 68 Current Accrued Expense is MXN301 Mil as of Jun. 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 68/100 and a GF Value™ of MXN445.80 (Fairly Valued). The stock has 4 warning signs investors should review.

Beam Therapeutics's Current Accrued Expense for the quarter that ended in Jun. 2026 was MXN301 Mil.

Beam Therapeutics's quarterly Current Accrued Expense declined from Dec. 2025 (MXN431 Mil) to Mar. 2026 (MXN423 Mil) and declined from Mar. 2026 (MXN423 Mil) to Jun. 2026 (MXN301 Mil).

Beam Therapeutics's annual Current Accrued Expense declined from Dec. 2023 (MXN1,040 Mil) to Dec. 2024 (MXN377 Mil) but then increased from Dec. 2024 (MXN377 Mil) to Dec. 2025 (MXN431 Mil).

Beam Therapeutics Current Accrued Expense Related Terms

Beam Therapeutics Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Current Accrued Expense Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only 1,005.99 361.22 1,039.66 377.18 431.06

Beam Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 510.48 423.79 431.06 423.03 301.48
MEX:BEAM
68GF Score
Beam Therapeutics Inc MEX:BEAM
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of MXN301 Mil mean?
Beam Therapeutics (MEX:BEAM) has a Current Accrued Expense of MXN301 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' Current Accrued Expense too high?
Beam Therapeutics' current Current Accrued Expense is MXN301 Mil. Overall, Beam Therapeutics has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Current Accrued Expense compare to KOD and TARS?
Beam Therapeutics' Current Accrued Expense of MXN301 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Current Accrued Expense is MXN301 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Fairly Valued. The stock's GF Value™ is MXN445.80, compared to a current price of MXN454.00 — trading 1.8% above its estimated fair value. The current Current Accrued Expense is MXN301 Mil. Beam Therapeutics' overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Current Accrued Expense is MXN301 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN454.00 is trading 1.8% above its estimated GF Value™ of MXN445.80. GuruFocus considers Beam Therapeutics to be Fairly Valued.

Key valuation signals for MEX:BEAM:

  • Current Accrued Expense: MXN301 Mil
  • GF Value™: MXN445.80 vs. price of MXN454.00 (1.8% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
68GF Score

Get the complete analysis for MEX:BEAM

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN454.00
Price
MXN445.80
GF Value